Alerts will be sent to your verified email
Verify EmailRPGLIFE
RPG Life Sciences
|
Panacea Biotec
|
Sequent Scientific
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Domestic Sales Growth - YoY
|
-11.18 % | n/a | n/a |
R&D as a % of Total Sales
|
1.5 % | 6.74 % | 0.0 |
Financials
|
|||
5 yr Average ROE
|
20.08 % | 19.34 % | 3.75 % |
5yr average Equity Multiplier
|
1.4 | 2.01 | 2.1 |
5yr Average Asset Turnover Ratio
|
1.26 | 0.39 | 0.87 |
5yr Avg Net Profit Margin
|
11.59 % | 20.95 % | 2.4 % |
Price to Book
|
7.05 | 0.97 | 4.79 |
P/E
|
30.13 | 0.0 | 0.0 |
5yr Avg Cash Conversion Cycle
|
-64.92 Days | -83.17 Days | 61.25 Days |
Inventory Days
|
63.34 Days | 118.8 Days | 70.72 Days |
Days Receivable
|
25.32 Days | 54.62 Days | 84.11 Days |
Days Payable
|
145.09 Days | 284.35 Days | 118.6 Days |
5yr Average Interest Coverage Ratio
|
17.66 | 2.91 | 2.9 |
5yr Avg ROCE
|
27.52 % | -10.17 % | 9.0 % |
5yr Avg Operating Profit Margin
|
19.94 % | -2.87 % | 10.83 % |
5 yr average Debt to Equity
|
0.02 | 0.41 | 0.46 |
5yr CAGR Net Profit
|
24.75 % | n/a | n/a |
5yr Average Return on Assets
|
14.44 % | 7.46 % | 1.98 % |
Shareholdings
|
|||
Promoter Holding
|
72.81 % | 73.59 % | 52.79 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.74 % | 0.0 | -1.07 % |
Change in Mutual Fund Holding (3 Yrs)
|
1.47 % | -1.27 % | 2.48 % |
RPG Life Sciences
|
Panacea Biotec
|
Sequent Scientific
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
Therapeutic Area Break-Up
|